Pharma Partnering US 2026: Biotech Dealmaking Outlook
Pharma Partnering Summit US 2026 focuses on BD&L deals, R&D collaborations, and M&A. Biotech partnering activity is accelerating, driven by licensing deals and strategic collaborations in oncology, rare diseases, and AI-integrated therapies.
Key Takeaways
- Pharma Partnering Summit US 2026 is set to be a key event for BD&L deals, R&D collaborations, investments, alliances, and M&A in the pharmaceutical and biotech sectors.
- Biotech partnering activity in the US is accelerating, fueled by licensing deals, M&A, and strategic global collaborations.
- Key areas of therapeutic interest include oncology, rare diseases, and AI-integrated therapies.
The Pharma Partnering Summit US 2026 will take place April 29–30, 2026, in San Diego, CA. This summit is designed to connect global business development and licensing (BD&L) leaders, focusing on fostering deals and collaborations that drive innovation in the pharmaceutical and biotech industries.
This event is particularly significant as the biotech industry sees increased partnering activity driven by licensing deals, mergers and acquisitions (M&A), and strategic global collaborations. With large pharmaceutical companies looking to bolster their pipelines and smaller biotechs seeking funding and expertise, the summit provides a crucial platform for deal-making and strategic discussions.
Event Overview
The Pharma Partnering Summit US 2026 offers a structured environment for senior executives to explore opportunities for collaboration and investment. Unlike scientific conferences that focus on late-breaking abstracts, this summit emphasizes company showcases, expert panels, and pre-arranged 1:2:1 meetings to facilitate deal-making.
Dealmaking Trends in US Biotech
Biotech partnering activity in the US is accelerating in 2026. Licensing deals, M&A, and venture funding are key drivers. Large pharmaceutical companies are actively seeking partnerships and acquisitions to address patent expirations and expand their portfolios.
In the first quarter of 2026, licensing deals reached an announced value of $77.3 billion, while M&A activity totaled $15.6 billion across 19 biopharma deals. Venture funding also played a crucial role, supporting early-stage biotech pipelines with $5.2 billion in investments.
Agenda Highlights
The summit's agenda is designed to provide attendees with insights into best practices for structuring successful deals and building strategic relationships.
Day 1 (April 29)
- Best Practices for Structuring Successful Deals
- Company Presentations: Multiple sessions where companies pitch their assets, platforms, and technologies.
- Assessing Emerging Trends and Therapeutic Areas
- Choosing the Right Partner
Day 2 (April 30)
- Building Relationships and Ensuring Role Clarity in Deals
- Company Presentations: Continued sessions for companies to showcase their offerings.
- Deal Making Between Biotech and Big Pharma
- Opportunities and Key Challenges in Global Partnering
Company showcases are a central feature, providing companies with 15-minute slots to pitch their assets and platforms to a BD&L audience. Expert panels offer insights into trends, deal strategies, and market dynamics. The event also facilitates over 12 hours of 1:2:1 meetings, enabling targeted networking and deal discussions.
Market & Investor Implications
The Pharma Partnering Summit US 2026 reflects the ongoing trend of increased collaboration and investment in the biotech sector. With large pharmaceutical companies facing patent cliffs and a need for innovative therapies, partnering with smaller biotechs becomes an attractive strategy. Venture funding continues to support early-stage pipelines, driving further innovation and deal-making opportunities.
What to Watch Next
As the summit approaches, keep an eye on announcements regarding specific company presentations and expert panel topics. Monitoring deal activity in the weeks following the summit will provide insights into the event's impact on the biotech partnering landscape.
Frequently Asked Questions
- What is the Pharma Partnering Summit US 2026?
- The Pharma Partnering Summit US 2026 is a conference focused on BD&L deals, R&D collaborations, investments, alliances, and M&A for pharma and biotech executives.
- Where and when will the summit take place?
- The summit will be held on April 29–30, 2026, in San Diego, CA.
- What are the key topics covered at the summit?
- Key topics include best practices for structuring deals, company presentations, emerging trends in therapeutic areas, and global partnering opportunities.
- What types of activities can attendees participate in?
- Attendees can participate in company showcases, expert panels, and pre-arranged 1:2:1 meetings.
- What are the current trends in US biotech partnering?
- Current trends include increased licensing deals, M&A activity, and strategic global collaborations, particularly in oncology, rare diseases, and AI-integrated therapies.
